Pharm Exec3d
Johnson & Johnson Initiates New Drug Application for TAR-200 in BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer
The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...
Targeted Oncology3d
FDA Considers TAR-200 in BCG-Unresponsive High-Risk NMIBC
An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...
Pharmaceutical Technology21d
Cetrelimab by Johnson & Johnson for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval
Cetrelimab is under clinical development by Johnson & Johnson and currently in Phase III for Muscle Invasive Bladder Cancer (MIBC). According to GlobalData, Phase III drugs for Muscle Invasive Bladder ...
clinicaltrialsarena1mon
Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial
PBGENE-HBV specifically targets the hepatitis B viral genome. Credit: Jarun Ontakrai/Shutterstock. Precision Biosciences has gained the approval of its clinical trial application (CTA) in Hong Kong to ...